TY - JOUR
T1 - Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit
AU - Begue, R. E.
AU - Castellares, G.
AU - Cabezas Sanchez, Cesar Augusto
AU - Sanchez, J. L.
AU - Meza, R.
AU - Watts, D. M.
AU - Taylor, D. N.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1995
Y1 - 1995
N2 - Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subjects, respectively. Within one year, titers decreased to levels close to baseline. A booster dose then induced rises similar to those which occurred after the initial vaccination. The results suggest that 1-year booster doses may be necessary to maintain immunity against cholera in Latin America.
AB - Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subjects, respectively. Within one year, titers decreased to levels close to baseline. A booster dose then induced rises similar to those which occurred after the initial vaccination. The results suggest that 1-year booster doses may be necessary to maintain immunity against cholera in Latin America.
UR - http://www.scopus.com/inward/record.url?scp=0029095709&partnerID=8YFLogxK
U2 - 10.1128/iai.63.9.3726-3728.1995
DO - 10.1128/iai.63.9.3726-3728.1995
M3 - Artículo
C2 - 7642315
AN - SCOPUS:0029095709
VL - 63
SP - 3726
EP - 3728
JO - Infection and Immunity
JF - Infection and Immunity
SN - 0019-9567
IS - 9
ER -